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Abstract 
Heart transplantation is a life-prolonging therapy for many patients with stage D heart failure and other forms 
of advanced heart disease. However, graft rejection and/or immunosuppression-related side effects are major 
causes of morbidity and death among heart transplant patients. Graft rejection monitoring remains a 
challenge. It would be desirable to be able to detect rejection early enough and specifically enough to prevent 
allograft dysfunction without unnecessary overimmunosuppression. Hitherto, the main technique employed in 
monitoring the rejection status of a transplanted heart has been endomyocardial biopsy (EMB), which allows 
rejection to be screened for and monitored on the basis of the extent and distribution of lymphocytic 
infiltrates and associated myocardial damage. However, EMB has significant limitations: it is invasive, its 
sensitivity is limited by sampling efficacy, and it suffers from considerable between-observer variability. 
Although many noninvasive techniques have been investigated, none so far has proved able to match the 
performance of EMB. Currently, a multiparametric approach is employed that comprises clinical examination 
for signs or symptoms of heart failure, EMBs, drug level monitoring, allograft function tests (mainly 
echocardiographic studies), and screening for allograft vasculopathy. Gene expression profiling may be a 
promising tool for this purpose. 
 
 
 
 
 
 
 
 
  
HEART TRANSPLANTATION is a life-prolonging procedure for many patients with stage D 
heart failure and other forms of advanced heart disease.
1
 However, even with the latest advances in 
immunosuppression, graft rejection is a major cause of death among heart transplant patients.
2
 
According to the Registry of the International Society for Heart and Lung Transplantation 
(ISHLT), rejection causes 12% of deaths occurring between 1 and 12 months after heart 
transplantation,
3
 and 20% to 50% of patients suffer at least 1 rejection episode during the first year 
posttransplantation.
4
 On the other hand, immunosuppression-related side effects lead to high 
morbidity and mortality rates.
2,3
 Graft rejection monitoring is still a challenge. It would be 
desirable to be able to detect rejection early enough and specifically enough to prevent allograft 
dysfunction without unnecessary overimmunosuppression. Gene expression profiling (GEP) seems 
to be a promising tool for this purpose.
5
 
SCREENING FOR AND MONITORING CARDIAC REJECTION: CLINICAL METHODS 
Hitherto, the main technique employed in monitoring the rejection status of a transplanted 
heart has been endomyocardial biopsy (EMB), which allows rejection to be screened for and 
monitored on the basis of the extent and distribution of lymphocytic infiltrates and associated 
myocardial damage.
6
 The goal of periodic EMB is to detect acute rejection before allograft 
dysfunction occurs. The latest version of the ISHLT EMB grading scheme
7
 establishes 4 
categories: 0R (absence of rejection); 1R (mild rejection: presence of an interstitial and/or 
perivascular infiltrate, with or without a focus of myocyte damage); 2R (moderate rejection: 
presence of 2 or more infiltrate foci with associated myocyte damage); and 3R (severe rejection: 
presence of a diffuse infiltrate with multifocal myocyte damage and/or edema, vasculitis, or 
hemorrhage). The letter “R” denotes “Revised Classification” to avoid confusion with the previous 
scheme, the 1990 working formulation.
8
 
 
EMB has significant limitations: it is invasive; it is expensive,
9
; its sensitivity is limited by 
sampling efficacy; it suffers from considerable between-observer variability; and it is difficult to 
interpret nodular endomyocardial infiltrates (so-called “Quilty lesions”).10 Also, although the 
incidence of complications is very low when EMB is performed by experienced staff, severe 
complications can arise, including pneumothorax, bleeding, pericardial tamponade secondary to 
perforation of the right ventricle, arrhythmias, fistulas between a coronary artery and the right 
ventricle, tricuspid regurgitation, damage to the carotid or femoral artery, and arterial-venous 
fistulas.
11
 There is no consensus among heart transplant centers or countries regarding the 
frequency with which EMBs should be performed, or for how long they should continue to be 
performed, but the current trend is to reduce their number; most US centers limit periodic EMBs to 
the first 5 years following heart transplantation,
12
 and most Spanish centers to the first year.
13
 The 
role of EMBs for rejection screening continues to be debated.
14,15
 
 
Many noninvasive techniques have been investigated as regards their capacity for early 
detection of rejection, including echocardiography, radionuclide imaging, magnetic resonance 
imaging, intramyocardial electrograms, immune system monitoring, and biochemical 
parameters.
16–18
 However, none of them so far has proved able to match the performance of EMB. 
Currently, a multiparametric approach is employed that comprises clinical examination for signs 
or symptoms of heart failure, EMBs, drug level monitoring, allograft function tests (mainly 
echocardiographic studies), and screening for allograft vasculopathy.
12
 At the same time, it is 
mandatory to be on the lookout for side effects or complications of immunosuppressive therapy, 
particularly nephrotoxicity, infection, and cancer. 
  
GENE EXPRESSION PROFILING AND HEART TRANSPLANTATION 
An approach that currently promises to be of utility is based on correlations between clinical 
states and the expression of certain genes. Although DNA defines a person's biological potential, it 
is the active transcription of DNA to RNA, followed by translation to protein that realizes this 
potential in accordance with his or her history, environmental context, and clinical situation. If a 
GEP can be identified that is sufficiently characteristic of a given physiological state, this profile 
can then be used to test whether the individual patient exhibits the state in question. If the GEP 
becomes manifest before clinical, biochemical, or histological signs, this allows earlier detection 
of disease states; and if it appears in tissue that can be obtained noninvasively, it may allow 
noninvasive diagnosis of conditions that were previously best diagnosed invasively. In certain 
cases, a GEP may indicate not a current or imminent disorder, but a physiological state that 
correlates with the future development of disease. 
 
Genes that are up-regulated during acute cellular rejection after heart transplantation are 
involved in a wide range of functions, including T-cell activation and migration, natural killer cell 
activation, stem cell mobilization, hematopoiesis, platelet function, alloimmune recognition, and 
steroid responsiveness. GEPs have been obtained both from heart tissue
19
 and from peripheral 
blood mononuclear cells (PBMC).
20–22
 For screening and monitoring purposes, the latter source 
has the great advantage over EMB of being noninvasive, which not only eliminates the risk of 
EMB-related complications, but also allows more frequent testing. 
 
Schoels et al.
20
 took 58 blood samples from 44 patients at the time of EMB and used real-time 
quantitative polymerase chain reaction (PCR) to study the expression of 39 genes, including 
cytokines and chemokines, in PBMC. PBMC from patients with ISHLT EMB grades ≥2 (ISHLT 
old classification
8
) differed significantly from those of patients with grades <2 as regards 
expression of the genes for perforin, CD95 ligand, granzyme B, RANTES, CXCR3, COX2, ENA 
78, and TGF-β1, and a group of 5 was identified (perforin, CD95L, RANTES, COX2, and 
SEC7/TIC) that, with appropriate thresholds, discriminated between the 2 EMB grade groups with 
a sensitivity of 84% and a specificity of 82%. 
 
PCR methods can only handle up to about 50 genes at a time. Much more efficient for the 
purposes of identifying GEPs are DNA microarrays, which can carry representatives of all the 
genes in the genome. In a study in which they compared PBMC from 7 patients of EMB grade 
≥3A (according to ISHLT old classification8) and 7 of grade ≤1A with regard to 22,215 DNA 
transcripts, Horwitz et al
21
 identified 91 transcripts (not all from different genes) that had 
significantly altered levels in the patients with rejection, and were able to discriminate between the 
groups with and without rejection by applying a clustering algorithm to data for 40 of these 91. 
Furthermore, when patients with rejection had been treated and their rejection largely resolved, 
they exhibited profiles intermediate between their previous (rejection) profiles and those of 
patients without rejection, thus confirming the relevance of the corresponding genes to rejection. 
The involvement of the apoptosis-related gene CFLAR and the oxidative stress-related gene SOD2 
was confirmed by real-time quantitative PCR. 
 
In the Cardiac Allograft Gene Expression Observational (CARGO) study,
23
 to date the largest 
and most systematic investigation of GEP for diagnosis of heart graft rejection, an RNA 
microarray of 50-mer oligonucleotides representing 7370 genes identified 97 genes as candidate 
biomarkers when used to analyze gene expression in 285 PBMC samples from 98 patients (247 
corresponding to ISHLT grade 0 EMB specimens and 38 to specimens with ISHLT grade ≥3A). 
Together with a further 155 genes known to be related to these 97 or otherwise involved in 
transplant rejection, their utility as markers of rejection was further examined by statistical workup 
of data from quantitative PCR analyses of 36 PBMC samples corresponding to grade ≥3A 
rejection and 109 corresponding to grade 0 EMBs (most of these samples had not been screened 
for gene expression by microarray analysis). Eventually, a discriminant equation involving a group 
of 11 genes was developed that, on the basis of its application to a set of 281 samples from heart 
transplant patients ≥1 year postoperation that was representative of the clinically observed EMB 
grade distribution, and using a diagnostic score threshold favoring negative predictive value 
(NPV), was estimated to have an NPV of 99.6%, a positive predictive value (PPV) of 6.8%, a 
sensitivity of 88.9%, and a specificity of 69.4% for grade ≥3A rejection. Using this equation, PCR 
of PBMC can allow patients with subthreshold scores to be spared the risk involved in routine 
surveillance EMB. The CARGO II study is currently being carried out to validate these results in 
an independent, mainly European, population. 
 
An unexpected and interesting feature of the CARGO data is that grade 1B EMB samples were 
associated with PBMC test scores similar to those of grade ≥3A samples and significantly higher 
than those of grade 2 samples (as well as grades 1A and 0).
23,24
 Although the import of this finding 
is still unclear, it suggests (if not the result of a combination of tissue sampling error and 
misclassification of EMB specimens by pathologists) that rejection, as reflected by PBMC GEPs, 
may be a 2-phase process. It was also noted that test scores in general tended to rise during the first 
year posttransplantation, and with them the optimal threshold for detection of rejection.
23
 Starling 
et al,
25
 using the test version recently given FDA market clearance as the AlloMap Molecular 
Expression Test (XDx, Brisbane, Calif, United States), found that this rise appeared to be largely 
due to weaning from steroids after heart transplantation, and concluded that the AlloMap test 
might be useful for monitoring this process as well as for ruling out rejection. Allograft 
vasculopathy has also been reported to be associated with higher AlloMap scores.
26
 
 
The CARGO/AlloMap studies mentioned above correlated test scores with current EMB 
status. The same research group also found that test scores could predict EMB-proven rejection 
weeks or months prior to the event,
27
 and that testing shortly after heart transplantation allowed the 
classification of patients as having low, medium, or high risk of future rejection.
28
 On the other 
hand, early posttransplantation ischemic injury has been reported to be associated with higher 
AlloMap scores recorded an average of 34 months after heart transplantation.
29
 
 
Although the performance of the AlloMap test has been tested in a large number of patients 
using EMB results as a reference method, EMB has significant shortcomings, notably tissue 
sampling error and between-pathologist differences in interpretation. The Invasive Monitoring 
Attenuation Through Gene Expression (IMAGE) study is currently being carried out to compare 
the AlloMap with EMB in regard to relevant clinical outcomes (graft dysfunction, rejection with 
hemodynamic compromise, death, EMB-related complications), quality of life, and resource 
utilization.
30
 
In those of the above studies that concerned rejection, it was cellular rejection that was 
considered. An important recent development has been the analysis of CARGO study data to 
identify a GEP for antibody-mediated rejection.
31
 This work is still in progress, but the results 
obtained so far are promising and indicate cross-linking between the processes of cellular and 
antibody-mediated rejection. 
 
In conclusion, the potential benefits of GEP of organ graft recipients are many.
32
 First, it 
eventually may be possible to diagnose rejection noninvasively and before tissue injury occurs; 
currently, it certainly seems possible to restrict the use of invasive techniques to a high-risk 
subgroup of patients identified by GEP at low cost. It has been estimated that the use of the 
AlloMap test could save US hospitals more than $15.7 million annually.
5,9
 Second, GEP may also 
allow prognosis of the outcome of rejection, and of responsiveness to therapy; prediction of future 
allograft function; and the individualization or optimization of immunosuppressive therapy and 
changes thereof. Finally, it may help in the development of mechanism-based therapy. Further 
studies are needed to fully address these important issues. 
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